Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Biliary Tract Diseases

Free Subscription Articles published in Hepatology Retrieve available abstracts of 225 articles: HTML format

Single Articles

March 2024
1. JONES DE, Beuers U, Bonder A, Carbone M, et al
   Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
   Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000864.
   PubMed     Abstract available
   
   
   
2. LAL BB, Alam S, Sibal A, Kumar K, et al
   Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency-related cholestasis.
   Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000828.
   PubMed     Abstract available
   
   
   
3. AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
   Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
   Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
   PubMed     Abstract available
   
   
   
4. PANDURANGI S, Mourya R, Nalluri S, Fei L, et al
   Diagnostic accuracy of serum matrix metalloproteinase-7 as a biomarker of biliary atresia in a large North American cohort.
   Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000827.
   PubMed     Abstract available
   
   
   
5. ZHUANG Y, Szabo G
   Reply to: How does bile acid-induced IRF3 phosphorylation mediate cholestatic liver and kidney injury? more need to be known.
   Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000816.
   PubMed    
   
   
   
6. KELLERER M, Javed S, Casar C, Will N, et al
   Antagonistic effects of the cytotoxic molecules granzyme B and TRAIL in the immunopathogenesis of sclerosing cholangitis.
   Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000830.
   PubMed     Abstract available
   
   
   
7. JIANG L, Yang Z
   Letter to the Editor: How does bile acid-induced IRF3 phosphorylation mediate cholestatic liver and kidney injury? ---more need to be known.
   Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000813.
   PubMed    
   
   
   
8. LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al
   Autoimmune diseases in primary sclerosing cholangitis and their first-degree relatives.
   Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000823.
   PubMed     Abstract available
   
   
   February 2024
9. ZHANG H, Zhu K, Zhang R, Guo Y, et al
   Oleic acid-PPARgamma-FABP4 loop fuels cholangiocarcinoma colonization in lymph node metastases microenvironment.
   Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000784.
   PubMed     Abstract available
   
   
   January 2024
10. WILBUR HC, Soares HP, Azad NS
    Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations.
    Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000760.
    PubMed     Abstract available
    
    
    
11. BARGELLINI I, Rimassa L, Masi G
    SIRT and chemotherapy in unresectable iCCA: Ready to take off.
    Hepatology. 2024;79:9-11.
    PubMed    
    
    
    
12. CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
    Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
    Hepatology. 2024;79:39-48.
    PubMed     Abstract available
    
    
    December 2023
13. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
    Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
    PubMed    
    
    
    
14. WIEGAND J, Franke A, Stein K, Trautwein C, et al
    Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
    PubMed    
    
    
    
15. KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al
    Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
    Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728.
    PubMed     Abstract available
    
    
    November 2023
16. GHOSH S, Devereaux MW, Liu C, Sokol RJ, et al
    LRH-1 agonist DLPC through STAT6 promotes macrophage polarization and prevents parenteral nutrition associated cholestasis in mice.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000690.
    PubMed     Abstract available
    
    
    
17. GEHL V, O'Rourke CJ, Andersen JB
    Immunogenomics of cholangiocarcinoma.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000688.
    PubMed     Abstract available
    
    
    
18. HE S, Peng Y, Wei Q
    Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000685.
    PubMed    
    
    
    
19. SLOOTER CD, van den Brand FF, Lleo A, Liberal R, et al
    Reply - Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000689.
    PubMed    
    
    
    
20. LIU ZP, Sun XH, Yu C, Yin XY, et al
    Letter to the Editor: How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma?
    Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000651.
    PubMed    
    
    
    
21. NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
    ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
    Hepatology. 2023;78:1337-1351.
    PubMed     Abstract available
    
    
    
22. YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
    Metabolic reprogramming and its clinical implication for liver cancer.
    Hepatology. 2023;78:1602-1624.
    PubMed     Abstract available
    
    
    October 2023
23. RATTI F, Marino R, Groot Koerkamp B, Aldrighetti L, et al
    Reply: "How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma".
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000659.
    PubMed    
    
    
    
24. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
    Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
    Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
    PubMed     Abstract available
    
    
    
25. HU YF, Ma WJ, Jin YW, Li FY, et al
    Adjuvant chemotherapy for resected biliary tract cancers: A fluorouracil-based scheme beats out a gemcitabine-based scheme for the win.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000634.
    PubMed    
    
    
    
26. 
    Erratum: Modulation of the tryptophan hydroxylase 1/monoamine oxidase-A/5-hydroxytryptamine/5-hydroxytryptamine receptor 2A/2B/2C axis regulates biliary proliferation and liver fibrosis during cholestasis.
    Hepatology. 2023;78:E86.
    PubMed    
    
    
    September 2023
27. GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
    Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
    PubMed     Abstract available
    
    
    
28. ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
    Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
    PubMed     Abstract available
    
    
    
29. SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al
    Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589.
    PubMed     Abstract available
    
    
    August 2023
30. PEISELER M, Tacke F
    Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
    Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.
    PubMed    
    
    
    
31. RATTI F, Marino R, Olthof PB, Pratschke J, et al
    Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine learning analytics model to optimize treatment allocation.
    Hepatology. 2023 Aug 3. doi: 10.1097/HEP.0000000000000554.
    PubMed     Abstract available
    
    
    
32. DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
    Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
    PubMed     Abstract available
    
    
    
33. BOWLUS CL, Levy C
    Optimizing treatment of primary biliary cholangitis: Is good, good enough?
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
    PubMed    
    
    
    July 2023
34. ZHAO L, Liu J, Li K, Zhang C, et al
    PTPN9 dephosphorylates FGFR2pY656/657 via interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.
    Hepatology. 2023 Jul 27. doi: 10.1097/HEP.0000000000000552.
    PubMed     Abstract available
    
    
    
35. LI Y, Li B, Xiao X, Qian Q, et al
    Itaconate inhibits CD103+ TRM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.
    Hepatology. 2023 Jul 26. doi: 10.1097/HEP.0000000000000549.
    PubMed     Abstract available
    
    
    
36. EDELINE J, Bridgewater J, Campillo-Gimenez B, Neveu E, et al
    Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials.
    Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000544.
    PubMed     Abstract available
    
    
    
37. 
    Retraction: Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000484.
    PubMed    
    
    
    
38. JEONG H, Yoo C
    Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial - author's reply.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000535.
    PubMed    
    
    
    
39. HU YF, Gu HF, Jin YW, Li FY, et al
    Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
    Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000532.
    PubMed    
    
    
    June 2023
40. SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
    Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
    Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
    PubMed     Abstract available
    
    
    
41. EKSER B, Sucu S, Mihaylov P, Emamaullee JA, et al
    Letter to the Editor mucosal gut microbiota in primary sclerosing cholangitis before and after liver transplantation: Are there other challenges?
    Hepatology. 2023 Jun 5. doi: 10.1097/HEP.0000000000000503.
    PubMed    
    
    
    May 2023
42. NEJAK-BOWEN K, Monga SP
    Wnt-beta-catenin in hepatobiliary homeostasis, injury, and repair.
    Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000495.
    PubMed     Abstract available
    
    
    
43. 
    Erratum: IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2023 May 15. doi: 10.1097/HEP.0000000000000040.
    PubMed    
    
    
    
44. SHU L, Li X, Liu Z, Li K, et al
    Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation.
    Hepatology. 2023 May 5. doi: 10.1097/HEP.0000000000000437.
    PubMed     Abstract available
    
    
    
45. JEONG H, Kim KP, Jeong JH, Hwang DW, et al
    Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
    Hepatology. 2023;77:1540-1549.
    PubMed     Abstract available
    
    
    
46. FORMAN LM, Sapisochin G, Assis DN, Arrive L, et al
    Reply: Living donor liver transplantation for people with PSC.
    Hepatology. 2023;77:E97-E98.
    PubMed    
    
    
    April 2023
47. MACKOWIAK B, Gao B
    Activation of cholangiocyte mTORC1 drives alcohol-induced ductular reaction.
    Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000416.
    PubMed    
    
    
    
48. RUSSI AE, Shivakumar P, Luo Z, Bezerra J, et al
    Plasticity between ILC2 subsets and amphiregulin expression regulate epithelial repair in biliary atresia.
    Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000418.
    PubMed     Abstract available
    
    
    
49. DANIEL N, Genua F, Jenab M, Mayen AL, et al
    The role of the gut microbiome in the development of hepatobiliary cancers.
    Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000406.
    PubMed     Abstract available
    
    
    
50. HARTL L, Reiberger T, Trauner M
    Reply: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000399.
    PubMed    
    
    
    
51. UMAR S, Nadeem A, Nadeem M
    Letter to the editor: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000398.
    PubMed    
    
    
    
52. HIRSCHFIELD GM, Shiffman ML, Gulamhusein A, Kowdley KV, et al
    Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
    Hepatology. 2023 Apr 6. doi: 10.1097/HEP.0000000000000395.
    PubMed     Abstract available
    
    
    
53. YOO C, Javle MM, Verdaguer Mata H, de Braud F, et al
    Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000365.
    PubMed     Abstract available
    
    
    
54. CABALLERO-CAMINO FJ, Rodrigues PM, Wangsell F, Agirre-Lizaso A, et al
    A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multi-organ activity and shows translational relevance to humans.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000376.
    PubMed     Abstract available
    
    
    
55. SINGH SP, Mondia N
    Letter to the Editor: Much more needed in natural history of Alagille syndrome.
    Hepatology. 2023;77:E78.
    PubMed    
    
    
    March 2023
56. HARTMANN P, Schnabl B
    Can a mucosal microbiota signature predict disease severity, survival, and disease recurrence in PSC?
    Hepatology. 2023;77:709-711.
    PubMed    
    
    
    February 2023
57. MAMMADOV RA, Visseren T, Roest HP, van der Laan LJW, et al
    Letter to Editor: the mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. is the dysbiosis index really predictive for the recurrence of psc?
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000338.
    PubMed    
    
    
    
58. LI J, Chen J, Lee PMY, Zhang J, et al
    Familial clustering of intrahepatic cholestasis of pregnancy: A nationwide population-based study in Denmark.
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000328.
    PubMed     Abstract available
    
    
    
59. HOLE MJ, Kaasen Jorgensen K, Holm K, Braadland PR, et al
    Reply: The mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. Is the dysbiosis index really predictive for the recurrence of PSC?
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000340.
    PubMed    
    
    
    
60. ZHANG J, Lyu Z, Li B, You Z, et al
    P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000317.
    PubMed     Abstract available
    
    
    
61. KUNDU D, Kennedy L, Zhou T, Ekser B, et al
    p16 INK4A drives non-alcoholic fatty liver disease phenotypes in high fat diet fed mice via biliary e2f1/foxo1/igf-1 signaling.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000307.
    PubMed     Abstract available
    
    
    
62. WU N, Zhou T, Carpino G, Baiocchi L, et al
    Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2-/- mice.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000310.
    PubMed     Abstract available
    
    
    
63. AMENT CE, Steinmann S, Evert K, Pes GM, et al
    Aberrant fucosylation sustains the NOTCH and EGFR/NF-kB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma.
    Hepatology. 2023 Feb 16. doi: 10.1097/HEP.0000000000000322.
    PubMed     Abstract available
    
    
    
64. VANDRIEL SM, Li LT, She H, Wang JS, et al
    Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study.
    Hepatology. 2023;77:512-529.
    PubMed     Abstract available
    
    
    
65. HABASH N, Ibrahim SH
    The Global Alagille Alliance study: Redefining the natural history of Alagille syndrome.
    Hepatology. 2023;77:347-349.
    PubMed    
    
    
    January 2023
66. ALI AH, Buness CW, Fischer R, Holtmann GJ, et al
    Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis.
    Hepatology. 2023 Jan 30. doi: 10.1097/HEP.0000000000000304.
    PubMed    
    
    
    
67. BOWLUS CL, Arrive L, Bergquist A, Deneau M, et al
    Reply: insurance should cover vancomycin for primary sclerosing cholangitis.
    Hepatology. 2023 Jan 26. doi: 10.1097/HEP.0000000000000305.
    PubMed    
    
    
    
68. LAMARCA A, Edeline J
    Adjuvant treatment for biliary tract tumours: lost in a maze?
    Hepatology. 2023 Jan 23. doi: 10.1097/HEP.0000000000000301.
    PubMed    
    
    
    
69. LI Y, Yang B, Miao H, Liu L, et al
    Nicotinamide N-methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000028.
    PubMed     Abstract available
    
    
    
70. UNALP-ARIDA A, Ruhl CE
    Increasing gallstone disease prevalence and associations with gallbladder and biliary tract mortality in the United States.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000264.
    PubMed     Abstract available
    
    
    
71. GUILLOT A, Winkler M, Silva Afonso M, Aggarwal A, et al
    Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000270.
    PubMed     Abstract available
    
    
    
72. SHORT C, Zhong A, Xu J, Mahdi E, et al
    TWEAK/FN14 promotes profibrogenic pathway activation in Prominin-1-expressing hepatic progenitor cells in biliary atresia.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000026.
    PubMed     Abstract available
    
    
    
73. LEE SH, So J, Shin D
    Hepatocyte-to-cholangiocyte conversion occurs through transdifferentiation independently of proliferation in zebrafish.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000016.
    PubMed     Abstract available
    
    
    
74. ZHANG L, Pan Q, Zhang L, Xia H, et al
    Runt-related transcription factor-1 ameliorates bile acid-induced hepatic inflammation in cholestasis through JAK/STAT3 signaling.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000041.
    PubMed     Abstract available
    
    
    
75. HELLEN DJ, Bennett A, Malla S, Klindt C, et al
    Liver-restricted deletion of the biliary atresia candidate gene Pkd1l1 causes bile duct dysmorphogenesis and ciliopathy.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000029.
    PubMed     Abstract available
    
    
    
76. NYHOLM I, Hukkinen M, Pihlajoki M, Davidson JR, et al
    Serum FGF19 predicts outcomes of Kasai portoenterostomy in biliary atresia.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000048.
    PubMed     Abstract available
    
    
    
77. MA J, Yang Z, Huang Z, Li L, et al
    Rngtt governs biliary-derived liver regeneration initiation by transcriptional regulation of mTORC1 and Dnmt1 in zebrafish.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000186.
    PubMed     Abstract available
    
    
    
78. CANTALLOPS VILA P, Ravichandra A, Agirre Lizaso A, Perugorria MJ, et al
    Heterogeneity, crosstalk and targeting of cancer associated fibroblasts in cholangiocarcinoma.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000206.
    PubMed     Abstract available
    
    
    
79. HEINEMANN M, Adam R, Karam V, Schramm C, et al
    Letter to the Editor: Living donor liver transplantation for people with PSC.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000208.
    PubMed    
    
    
    September 2022
80. BORAD MJ, Bai LY, Richards D, Mody K, et al
    Silmitasertib Plus Gemcitabine and Cisplatin First-Line Therapy in Locally Advanced/Metastatic Cholangiocarcinoma: a Phase 1b/2 Study.
    Hepatology. 2022 Sep 24. doi: 10.1002/hep.32804.
    PubMed     Abstract available
    
    
    
81. HARPAVAT S, Hawthorne K, Setchell KDR, Narvaez Rivas M, et al
    Serum Bile Acids as a New Prognostic Biomarker in Biliary Atresia Following Kasai Portoenterostomy.
    Hepatology. 2022 Sep 21. doi: 10.1002/hep.32800.
    PubMed     Abstract available
    
    
    
82. BIAGIOLI M, Marchiano S, di Giorgio C, Roselli R, et al
    Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32787.
    PubMed     Abstract available
    
    
    
83. BOWLUS CL, Arrive L, Bergquist A, Deneau M, et al
    AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma.
    Hepatology. 2022 Sep 9. doi: 10.1002/hep.32771.
    PubMed    
    
    
    
84. LEUNG DH, Devaraj S, Goodrich NP, Chen X, et al
    Serum Biomarkers Correlated with Liver Stiffness Assessed in a Multi-center Study of Pediatric Cholestatic Liver Disease.
    Hepatology. 2022 Sep 7. doi: 10.1002/hep.32777.
    PubMed     Abstract available
    
    
    
85. HOLE MJ, Kaasen Jorgensen K, Holm K, Braadland PR, et al
    A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation.
    Hepatology. 2022 Sep 3. doi: 10.1002/hep.32773.
    PubMed     Abstract available
    
    
    August 2022
86. MAYO MJ
    Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
    Hepatology. 2022;76:518-531.
    PubMed     Abstract available
    
    
    
87. ZHANG X, Wang Z, Tang W, Wang X, et al
    Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.
    Hepatology. 2022;76:317-329.
    PubMed     Abstract available
    
    
    July 2022
88. HEUCKE N, Keitel V
    COVID-19-associated cholangiopathy: What's left after the virus has gone?
    Hepatology. 2022 Jul 13. doi: 10.1002/hep.32668.
    PubMed    
    
    
    
89. HARTL L, Reiberger T, Trauner M
    On the development of secondary sclerosing cholangitis in chronic liver disease patients after COVID-19.
    Hepatology. 2022 Jul 12. doi: 10.1002/hep.32664.
    PubMed    
    
    
    June 2022
90. DENG M, Ran P, Chen L, Wang Y, et al
    Proteogenomic Characterization of Cholangiocarcinoma.
    Hepatology. 2022 Jun 18. doi: 10.1002/hep.32624.
    PubMed     Abstract available
    
    
    
91. 
    Retracted: Posttranslational regulation of polycystin-2 protein expression as a novel mechanism of cholangiocyte reaction and repair from biliary damage.
    Hepatology. 2022 Jun 17. doi: 10.1002/hep.32595.
    PubMed     Abstract available
    
    
    
92. XU J, Wang Y, Khoshdeli M, Peach M, et al
    IL-31 Levels Correlate with Pruritus in Patients with Cholestatic and Metabolic Liver Diseases and is FXR Responsive in NASH.
    Hepatology. 2022 Jun 10. doi: 10.1002/hep.32599.
    PubMed     Abstract available
    
    
    May 2022
93. HARTL L, Haslinger K, Angerer M, Semmler G, et al
    Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32582.
    PubMed     Abstract available
    
    
    
94. SMIRNOVA E, Muthiah MD, Narayan N, Siddiqui MS, et al
    Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32568.
    PubMed     Abstract available
    
    
    
95. ANDERSEN JB
    Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32558.
    PubMed    
    
    
    
96. ZHOU J, Sun Y, Zhang W, Yuan J, et al
    Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis.
    Hepatology. 2022 May 1. doi: 10.1002/hep.32548.
    PubMed     Abstract available
    
    
    April 2022
97. JIANG ST, Zhang L, Xu YY, Lu X, et al
    Letter to the editor: For the core set of bile lipidome and meta-proteome signature, repeatability is the key.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32543.
    PubMed    
    
    
    
98. SHARMA N, Yadav M, Tripathi G, Mathew B, et al
    Response to Letter to the editor: For the core set of bile lipidome and meta-proteome signature, repeatability is the key.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32541.
    PubMed    
    
    
    
99. SHCHEYNIKOV N, Boggs K, Green A, Feranchak AP, et al
    Identification of the Chloride Channel, Leucine-Rich Repeat-Containing Protein 8, subfamily A (LRRC8A), in Mouse Cholangiocytes.
    Hepatology. 2022 Apr 21. doi: 10.1002/hep.32536.
    PubMed     Abstract available
    
    
    
100. MOHAMAD ZAKI NH, Shiota J, Calder AN, Keeley TM, et al
     C-X-C motif chemokine ligand 1 induced by Hedgehog signaling promotes mouse extrahepatic bile duct repair after acute injury.
     Hepatology. 2022 Apr 7. doi: 10.1002/hep.32492.
     PubMed     Abstract available
     
     
     
101. MANDATO C, Vajro P
     Letter to the Editor: The burgeoning field of Progressive Familial Intrahepatic Cholestasis.
     Hepatology. 2022 Apr 5. doi: 10.1002/hep.32489.
     PubMed    
     
     
     March 2022
102. SHARMA N, Yadav M, Tripathi G, Mathew B, et al
     Bile multi-omics analysis classifies lipid species and microbial peptides predictive of Carcinoma of Gall bladder.
     Hepatology. 2022 Mar 31. doi: 10.1002/hep.32496.
     PubMed     Abstract available
     
     
     
103. JAVITT NB
     Letter to the Editor: Hyperosmolarity during hepatic bile formation:Overlooked significance.
     Hepatology. 2022 Mar 29. doi: 10.1002/hep.32482.
     PubMed    
     
     
     
104. HENGSTLER JG, Oude Elferink R, van de Graaf SF, Drasdo D, et al
     The de-micellization hypothesis of water influx into bile ducts.
     Hepatology. 2022 Mar 28. doi: 10.1002/hep.32485.
     PubMed    
     
     
     
105. WANG T, Xu C, Zhang Z, Wu H, et al
     Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression.
     Hepatology. 2022 Mar 27. doi: 10.1002/hep.32483.
     PubMed     Abstract available
     
     
     
106. BASS LM, Ye W, Hawthorne K, Leung DH, et al
     The Risk of Variceal Hemorrhage and Pre-Transplant Mortality in Children with Biliary Atresia.
     Hepatology. 2022 Mar 10. doi: 10.1002/hep.32451.
     PubMed     Abstract available
     
     
     
107. 
     Erratum for Nevi, et al. DCLK1, a putative stem cell marker in human cholangiocarcinoma.
     Hepatology. 2022;75:773.
     PubMed    
     
     
     
108. IBRAHIM SH, Kamath BM, Loomes KM, Karpen SJ, et al
     Cholestatic Liver Diseases of Genetic Etiology: Advances and Controversies.
     Hepatology. 2022 Mar 1. doi: 10.1002/hep.32437.
     PubMed     Abstract available
     
     
     February 2022
109. WU MJ, Shi L, Merritt J, Zhu AX, et al
     Biology of IDH Mutant Cholangiocarcinoma.
     Hepatology. 2022 Feb 28. doi: 10.1002/hep.32424.
     PubMed     Abstract available
     
     
     
110. ROBERTS SB, Hirschfield GM, Worobetz LJ, Vincent C, et al
     Ethnicity, disease severity and survival in Canadian patients with Primary Biliary Cholangitis.
     Hepatology. 2022 Feb 26. doi: 10.1002/hep.32426.
     PubMed     Abstract available
     
     
     
111. CHAUDHRY HUR, Hayat A, Ahmad A
     Letter to the Editor: Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study.
     Hepatology. 2022 Feb 19. doi: 10.1002/hep.32416.
     PubMed    
     
     
     
112. JEON Y, Kwon SM, Rhee H, Yoo JE, et al
     Molecular and radio-pathologic spectrum between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
     Hepatology. 2022 Feb 5. doi: 10.1002/hep.32397.
     PubMed     Abstract available
     
     
     
113. LUO C, Xin H, Zhou Z, Hu Z, et al
     Tumor-Derived Exosomes Induce Immunosuppressive Macrophages to Foster Intrahepatic Cholangiocarcinoma Progression.
     Hepatology. 2022 Feb 2. doi: 10.1002/hep.32387.
     PubMed     Abstract available
     
     
     
114. YANG Y, Choi J, Chen Y, Invernizzi P, et al
     E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants.
     Hepatology. 2022;75:266-279.
     PubMed     Abstract available
     
     
     January 2022
115. RUIZ DE GAUNA M, Biancaniello F, Gonzalez-Romero F, Rodrigues PM, et al
     Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids.
     Hepatology. 2022 Jan 14. doi: 10.1002/hep.32344.
     PubMed     Abstract available
     
     
     
116. ANDERSSON ER
     Outside influence: the extrahepatic duct as a source for bile duct regeneration.
     Hepatology. 2022 Jan 10. doi: 10.1002/hep.32334.
     PubMed    
     
     
     
117. SHIODE Y, Kodama T, Shigeno S, Murai K, et al
     Traf3 inactivation promotes the development of intrahepatic cholangiocarcinoma via NIK-mediated hepatocyte transdifferentiation.
     Hepatology. 2022 Jan 7. doi: 10.1002/hep.32317.
     PubMed     Abstract available
     
     
     
118. 
     Retracted: Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies.
     Hepatology. 2022 Jan 7. doi: 10.1002/hep.32246.
     PubMed    
     
     
     December 2021
119. PASTOR CM
     Reply to the review <>.
     Hepatology. 2021 Dec 27. doi: 10.1002/hep.32296.
     PubMed    
     
     
     
120. VARTAK N, Hengstler JG
     REPLY TO HEP-21-2202: Analysis and limits of detection of biliary flux.
     Hepatology. 2021 Dec 25. doi: 10.1002/hep.32297.
     PubMed    
     
     
     
121. MASYUK AI, Masyuk TV, Trussoni CE, Pirius NE, et al
     Autophagy Promotes Hepatic Cystogenesis in Polycystic Liver Disease via Depletion of Cholangiocyte Ciliogenic Proteins.
     Hepatology. 2021 Dec 23. doi: 10.1002/hep.32298.
     PubMed     Abstract available
     
     
     
122. REMETIC J, Ghallab A, Hobloss Z, Brackhagen L, et al
     Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance.
     Hepatology. 2021 Dec 20. doi: 10.1002/hep.32289.
     PubMed     Abstract available
     
     
     
123. SAPISOCHIN G, Ivanics T, Heimbach J
     Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time?
     Hepatology. 2021 Dec 3. doi: 10.1002/hep.32258.
     PubMed     Abstract available
     
     
     November 2021
124. RUBINO JG, Flemming JA
     Menopausal hormone therapy and risk of biliary tract cancers: addressing the ant, not the elephant in the room.
     Hepatology. 2021 Nov 25. doi: 10.1002/hep.32254.
     PubMed     Abstract available
     
     
     
125. JACKSON SS, Pfeiffer RM, Gabbi C, Anderson L, et al
     Menopausal hormone therapy and risk of biliary tract cancers.
     Hepatology. 2021 Nov 11. doi: 10.1002/hep.32198.
     PubMed     Abstract available
     
     
     
126. LI H, Lan T, Liu H, Liu C, et al
     IL-6 induced cGGNBP2 encodes a novel protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
     Hepatology. 2021 Nov 10. doi: 10.1002/hep.32232.
     PubMed     Abstract available
     
     
     
127. WU N, Carpino G, Ceci L, Baiocchi L, et al
     MT1 but not MT2 melatonin receptor knockout decreases biliary damage and liver fibrosis during cholestatic liver injury.
     Hepatology. 2021 Nov 7. doi: 10.1002/hep.32233.
     PubMed     Abstract available
     
     
     
128. LEE BT, Tana MM, Kahn JA, Dara L, et al
     We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases.
     Hepatology. 2021;74:2876-2887.
     PubMed     Abstract available
     
     
     October 2021
129. ZIMMER CL, Filipovic I, Cornillet M, O'Rourke CJ, et al
     MAIT cell tumor infiltration predicts long-term survival in cholangiocarcinoma.
     Hepatology. 2021 Oct 30. doi: 10.1002/hep.32222.
     PubMed     Abstract available
     
     
     
130. KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
     Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
     Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
     PubMed     Abstract available
     
     
     
131. LINDOR KD, Dawson PA, Trauner M
     Alan Hofmann (1931-2021): A Career Well Spent Understanding Bile Acids.
     Hepatology. 2021 Oct 18. doi: 10.1002/hep.32206.
     PubMed     Abstract available
     
     
     
132. FAIRFIELD CJ, Drake TM, Pius R, Bretherick AD, et al
     Genome-wide Analysis Identifies Novel Gallstone-susceptibility Loci Including Genes Regulating Gastrointestinal Motility.
     Hepatology. 2021 Oct 15. doi: 10.1002/hep.32199.
     PubMed     Abstract available
     
     
     
133. GRAHAM JJ, Mukherjee S, Yuksel M, Sanabria Mateos R, et al
     Aberrant hepatic trafficking of gut-derived T-cells is not specific to primary sclerosing cholangitis.
     Hepatology. 2021 Oct 11. doi: 10.1002/hep.32193.
     PubMed     Abstract available
     
     
     
134. CHEN L, Yang H, Li H, He C, et al
     Novel insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study.
     Hepatology. 2021 Oct 8. doi: 10.1002/hep.32183.
     PubMed     Abstract available
     
     
     
135. LLEO A, Hirschfield GM
     Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?
     Hepatology. 2021;74:2307.
     PubMed    
     
     
     
136. MA Y, Su H, Yuksel M, Longhi MS, et al
     Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry.
     Hepatology. 2021;74:2032-2046.
     PubMed     Abstract available
     
     
     September 2021
137. ZHAO C, Lancman JJ, Yang Y, Gates KP, et al
     Intrahepatic cholangiocyte regeneration from an Fgf-dependent extrahepatic progenitor niche in a zebrafish model of Alagille Syndrome.
     Hepatology. 2021 Sep 27. doi: 10.1002/hep.32173.
     PubMed     Abstract available
     
     
     
138. HUNG HY, Wang CC, Wei JC
     Letter to the Editor: Postdiagnosis aspirin use associated with decreased biliary tract cancer?
     Hepatology. 2021 Sep 23. doi: 10.1002/hep.32170.
     PubMed     Abstract available
     
     
     
139. VARTAK N, Hengstler JG
     Response to 21-1766: Challenging the dogma of canalicular bile flow.
     Hepatology. 2021 Sep 21. doi: 10.1002/hep.32168.
     PubMed     Abstract available
     
     
     
140. ZHOU SL, Luo CB, Song CL, Zhou ZJ, et al
     Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma.
     Hepatology. 2021 Sep 20. doi: 10.1002/hep.32164.
     PubMed     Abstract available
     
     
     
141. JAVITT NB, Boyer JL
     Letter to the Editor: On the Mechanisms of Biliary Flux.
     Hepatology. 2021 Sep 20. doi: 10.1002/hep.32167.
     PubMed     Abstract available
     
     
     
142. DE JONG IEM, Overi D, Carpino G, Gouw ASH, et al
     Persistent Biliary Hypoxia and Lack of Regeneration Are Key Mechanisms in the Pathogenesis of Post-transplant Non-anastomotic Strictures.
     Hepatology. 2021 Sep 20. doi: 10.1002/hep.32166.
     PubMed     Abstract available
     
     
     
143. CARAPETO F, Bozorgui B, Shroff RT, Chagani S, et al
     The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma.
     Hepatology. 2021 Sep 12. doi: 10.1002/hep.32150.
     PubMed     Abstract available
     
     
     
144. AN J, Kim D, Oh B, Oh YJ, et al
     Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
     Hepatology. 2021 Sep 3. doi: 10.1002/hep.32135.
     PubMed     Abstract available
     
     
     
145. WANG SS, Tang XT, Lin M, Yuan J, et al
     Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer-Associated Fibroblasts Formed After Chronic Liver Injuries.
     Hepatology. 2021;74:1578-1594.
     PubMed     Abstract available
     
     
     
146. WANG Y, Hylemon PB, Zhou H
     Long Noncoding RNA H19: A Key Player in Liver Diseases.
     Hepatology. 2021;74:1652-1659.
     PubMed    
     
     
     August 2021
147. VEDELD HM, Grimsrud MM, Andresen K, Pharo HD, et al
     Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile.
     Hepatology. 2021 Aug 26. doi: 10.1002/hep.32125.
     PubMed     Abstract available
     
     
     
148. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
     Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.
     Hepatology. 2021 Aug 24. doi: 10.1002/hep.32117.
     PubMed     Abstract available
     
     
     
149. ARORA M, Bogenberger JM, Abdelrahman AM, Yonkus J, et al
     Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers.
     Hepatology. 2021 Aug 18. doi: 10.1002/hep.32102.
     PubMed     Abstract available
     
     
     
150. AMARACHINTHA SP, Mourya R, Ayabe H, Yang L, et al
     Biliary organoids uncover delayed epithelial development and barrier function in biliary atresia.
     Hepatology. 2021 Aug 15. doi: 10.1002/hep.32107.
     PubMed     Abstract available
     
     
     
151. EL KASMI KC, Ghosh S, Anderson AL, Devereaux MW, et al
     Pharmacologic Activation of Hepatic Farnesoid X Receptor Prevents Parenteral Nutrition Associated Cholestasis in Mice.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32101.
     PubMed     Abstract available
     
     
     
152. LIN Y, Cai Q, Chen Y, Shi T, et al
     CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5-lipoxygenase.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32099.
     PubMed     Abstract available
     
     
     
153. ZENG R, Sha W, Leung FW, Chen H, et al
     Letter to the Editor: Proton pump inhibitors and Biliary Tract Cancer Risk: Causality or Reverse Causality?
     Hepatology. 2021 Aug 5. doi: 10.1002/hep.32090.
     PubMed     Abstract available
     
     
     July 2021
154. PANT K, Peixoto E, Richard S, Biswas A, et al
     Histone Deacetylase SIRT1 promotes loss of primary cilia in Cholangiocarcinoma.
     Hepatology. 2021 Jul 29. doi: 10.1002/hep.32080.
     PubMed     Abstract available
     
     
     
155. CAI P, Mao X, Zhao J, Nie L, et al
     Farnesoid X Receptor is Required for the Redifferentiation of Bi-potential Progenitor Cells during Biliary-Mediated Zebrafish Liver Regeneration.
     Hepatology. 2021 Jul 28. doi: 10.1002/hep.32076.
     PubMed     Abstract available
     
     
     
156. WADHWANI SI, Gottlieb L, Bucuvalas JC, Lyles C, et al
     Addressing social adversity to improve outcomes for children after liver transplant.
     Hepatology. 2021 Jul 28. doi: 10.1002/hep.32073.
     PubMed     Abstract available
     
     
     
157. GHOSH S, Devereaux MW, Anderson AL, Gehrke S, et al
     NFkappaB regulation of LRH-1 and ABCG5/8 potentiates phytosterol role in the pathogenesis of parenteral nutrition associated cholestasis.
     Hepatology. 2021 Jul 26. doi: 10.1002/hep.32071.
     PubMed     Abstract available
     
     
     
158. LOBE C, Vallette M, Arbelaiz A, Gonzalez-Sanchez E, et al
     ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and tumor-stroma paracrine signaling.
     Hepatology. 2021 Jul 23. doi: 10.1002/hep.32069.
     PubMed     Abstract available
     
     
     
159. ZHANG JW, Yang X, Ding HR, Zhang L, et al
     Is aspirin a drug or just a marker for biliary cancer?
     Hepatology. 2021 Jul 9. doi: 10.1002/hep.32052.
     PubMed     Abstract available
     
     
     
160. LEE MH, Huang YH, Koshiol J
     Response Letter Regarding Article, "Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort".
     Hepatology. 2021 Jul 8. doi: 10.1002/hep.32051.
     PubMed     Abstract available
     
     
     
161. DE GOEIJ FHC, Schlegel A, Muiesan P, Guarrera JV, et al
     Hypothermic oxygenated machine perfusion protects from cholangiopathy in DCD liver transplantation.
     Hepatology. 2021 Jul 7. doi: 10.1002/hep.32044.
     PubMed     Abstract available
     
     
     
162. WANG H, Song X, Liao H, Wang P, et al
     Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
     Hepatology. 2021;74:248-263.
     PubMed     Abstract available
     
     
     June 2021
163. VARTAK N, Drasdo D, Geisler F, Itoh T, et al
     On the mechanisms of biliary flux.
     Hepatology. 2021 Jun 23. doi: 10.1002/hep.32027.
     PubMed     Abstract available
     
     
     
164. SHI S, Chen S, Verstegen MMA, Pan Q, et al
     Letter to the Editor: HMGB1 Release is a Newly Identified Driver of Inflammation in the Pathogenesis of Biliary Atresia.
     Hepatology. 2021 Jun 23. doi: 10.1002/hep.32026.
     PubMed     Abstract available
     
     
     
165. MEADOWS V, Kennedy L, Ekser B, Kyritsi K, et al
     Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis via Farnesoid X Receptor Signaling.
     Hepatology. 2021 Jun 23. doi: 10.1002/hep.32028.
     PubMed     Abstract available
     
     
     
166. BARRON-MILLAR B, Ogle L, Mells G, Flack S, et al
     The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
     Hepatology. 2021 Jun 15. doi: 10.1002/hep.32011.
     PubMed     Abstract available
     
     
     
167. LEE YT, Wang JJ, Luu M, Noureddin M, et al
     Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
     Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.
     PubMed     Abstract available
     
     
     
168. KYRITSI K, Kennedy L, Meadows V, Hargrove L, et al
     Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
     Hepatology. 2021;73:2397-2410.
     PubMed     Abstract available
     
     
     May 2021
169. LEPORE A, Choy PM, Lee NC, Carella MA, et al
     Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth.
     Hepatology. 2021 May 28. doi: 10.1002/hep.31983.
     PubMed     Abstract available
     
     
     
170. SUN LY, Hu JY, Liang L, Tong XM, et al
     Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
     Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
     PubMed     Abstract available
     
     
     
171. JOHN BV, Deng Y, Martin P, Levy C, et al
     Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
     Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
     PubMed     Abstract available
     
     
     
172. KAMAL H, Sadr-Azodi O, Engstrand L, Brusselaers N, et al
     Association between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: a Swedish Population-Based Cohort Study.
     Hepatology. 2021 May 21. doi: 10.1002/hep.31914.
     PubMed     Abstract available
     
     
     
173. MARTINEZ M, Perito ER, Valentino P, Mack CL, et al
     Recurrence of primary sclerosing cholangitis after liver transplant in children: an international observational study.
     Hepatology. 2021 May 18. doi: 10.1002/hep.31911.
     PubMed     Abstract available
     
     
     
174. JANSSON H, Sparrelid E
     Letter to the Editor: The role of surgery in multiple intrahepatic cholangiocarcinoma should not be dismissed without further analysis.
     Hepatology. 2021 May 18. doi: 10.1002/hep.31905.
     PubMed     Abstract available
     
     
     
175. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
     Reply to (20-1119.R1) Surgery for advanced intrahepatic cholangiocarcinoma warrants further investigation.
     Hepatology. 2021 May 17. doi: 10.1002/hep.31904.
     PubMed     Abstract available
     
     
     
176. GENTILINI A, Lori G, Caligiuri A, Raggi C, et al
     Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells.
     Hepatology. 2021 May 6. doi: 10.1002/hep.31888.
     PubMed     Abstract available
     
     
     
177. LIAO SF, Koshiol J, Huang YH, Jackson SS, et al
     Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort.
     Hepatology. 2021 May 3. doi: 10.1002/hep.31879.
     PubMed     Abstract available
     
     
     
178. VAN DER LAAN LJW, Roos FJM, Verstegen MMA
     Bile Duct Repair in Human Liver Grafts: Effective Cholangiocyte Organoid Engraftment and Plasticity.
     Hepatology. 2021 May 2. doi: 10.1002/hep.31877.
     PubMed     Abstract available
     
     
     April 2021
179. YOON JG, Kim MH, Jang M, Kim H, et al
     Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and PD-1/PD-L1 Blockade Responses.
     Hepatology. 2021 Apr 21. doi: 10.1002/hep.31862.
     PubMed     Abstract available
     
     
     
180. XU Y, Leng K, Yao Y, Kang P, et al
     A Circular RNA, Cholangiocarcinoma-Associated Circular RNA 1, Contributes to Cholangiocarcinoma Progression, Induces Angiogenesis, and Disrupts Vascular Endothelial Barriers.
     Hepatology. 2021;73:1419-1435.
     PubMed     Abstract available
     
     
     
181. OSTROUMOV D, Duong S, Wingerath J, Woller N, et al
     Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
     Hepatology. 2021;73:1399-1418.
     PubMed     Abstract available
     
     
     March 2021
182. DI-LUOFFO M, Pirenne S, Saandi T, Loriot A, et al
     A novel mouse model of cholangiocarcinoma uncovers a role for Tensin-4 in tumor progression.
     Hepatology. 2021 Mar 26. doi: 10.1002/hep.31834.
     PubMed     Abstract available
     
     
     
183. BOERNER T, Drill E, Pak LM, Nguyen B, et al
     Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
     Hepatology. 2021 Mar 25. doi: 10.1002/hep.31829.
     PubMed     Abstract available
     
     
     
184. LUO X, Campbell NA, He L, O'Brien DR, et al
     SULF2 monoclonal antibody 5D5 suppresses human cholangiocarcinoma xenograft growth via regulation of a SULF2-PDGFRbeta-YAP signaling axis.
     Hepatology. 2021 Mar 18. doi: 10.1002/hep.31817.
     PubMed     Abstract available
     
     
     
185. WADA Y, Shimada M, Yamamura K, Toshima T, et al
     A transcriptomic signature for risk-stratification and recurrence prediction in intrahepatic cholangiocarcinoma.
     Hepatology. 2021 Mar 16. doi: 10.1002/hep.31803.
     PubMed     Abstract available
     
     
     
186. CRISTOFERI L, Calvaruso V, Overi D, Vigano M, et al
     Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naive patients with Primary Biliary Cholangitis: a dual cut-off approach.
     Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810.
     PubMed     Abstract available
     
     
     
187. KENDRE G, Marhenke S, Lorz G, Becker D, et al
     The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion - driven cholangiocarcinoma.
     Hepatology. 2021 Mar 11. doi: 10.1002/hep.31799.
     PubMed     Abstract available
     
     
     
188. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
     Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency.
     Hepatology. 2021 Mar 5. doi: 10.1002/hep.31787.
     PubMed     Abstract available
     
     
     
189. ZHOU Y, Chen Y, Zhang X, Xu Q, et al
     Brg1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
     Hepatology. 2021 Mar 2. doi: 10.1002/hep.31780.
     PubMed     Abstract available
     
     
     February 2021
190. CHIU M, Garabon J, Chen L, Karp N, et al
     Mevalonic Aciduria Associated with Intrahepatic Bile Duct Paucity.
     Hepatology. 2021 Feb 27. doi: 10.1002/hep.31778.
     PubMed     Abstract available
     
     
     
191. JOHNSON KM, Fischer RT, Holtmann GJ, Shah A, et al
     Letter to the editor: Oral vancomycin versus no therapy for pediatric primary sclerosing cholangitis.
     Hepatology. 2021 Feb 26. doi: 10.1002/hep.31764.
     PubMed     Abstract available
     
     
     
192. SHIOTA J, Samuelson LC, Razumilava N
     Hepatobiliary organoids and their applications for studies of liver health and disease: are we there yet?
     Hepatology. 2021 Feb 26. doi: 10.1002/hep.31772.
     PubMed     Abstract available
     
     
     
193. JOHN BV, Aitcheson G, Schwartz KB, Shabbir Khakoo N, et al
     Male Gender is Associated with Higher Rates of Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis.
     Hepatology. 2021 Feb 26. doi: 10.1002/hep.31776.
     PubMed     Abstract available
     
     
     
194. DAT NQ, Thuy LTT, Hieu VN, Hai H, et al
     6His-tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.
     Hepatology. 2021 Feb 11. doi: 10.1002/hep.31752.
     PubMed     Abstract available
     
     
     
195. MOHANTY SK, Donnelly B, Temple H, Ortiz-Perez A, et al
     HMGB1 release by cholangiocytes governs biliary atresia pathogenesis and correlates with increases in afflicted infants.
     Hepatology. 2021 Feb 8. doi: 10.1002/hep.31745.
     PubMed     Abstract available
     
     
     
196. JAVITT NB
     Letter to the Editor: Intravital dynamic and correlative imaging reveals diffusion-dominated canalicular and flow-augmented ductular bile flux.
     Hepatology. 2021 Feb 8. doi: 10.1002/hep.31746.
     PubMed     Abstract available
     
     
     
197. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
     Reply to "Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?"; multiple primaries vs liver metastases.
     Hepatology. 2021 Feb 7. doi: 10.1002/hep.31740.
     PubMed     Abstract available
     
     
     
198. ZHANG XF, Lv Y, Pawlik TM
     Letter to the editor: Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?
     Hepatology. 2021 Feb 6. doi: 10.1002/hep.31741.
     PubMed     Abstract available
     
     
     
199. NASSER-GHODSI N, Mara K, Watt KD
     De novo Colorectal and Pancreatic Cancer in Liver Transplant Recipients: Identifying the Higher Risk Populations.
     Hepatology. 2021 Feb 5. doi: 10.1002/hep.31731.
     PubMed     Abstract available
     
     
     January 2021
200. ITOH A, Adams D, Huang W, Wu Y, et al
     Enoxacin upregulates microRNA biogenesis and downregulates cytotoxic CD8 T cell function in autoimmune cholangitis.
     Hepatology. 2021 Jan 19. doi: 10.1002/hep.31724.
     PubMed     Abstract available
     
     
     
201. LI J, Ye X, He S
     Letter to the Editor: Imaging monitoring of primary sclerosing cholangitis patients.
     Hepatology. 2021 Jan 11. doi: 10.1002/hep.31709.
     PubMed     Abstract available
     
     
     
202. ASSIS DN, Levy C
     Oral Vancomycin or Ursodeoxycholic acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials.
     Hepatology. 2021 Jan 5. doi: 10.1002/hep.31702.
     PubMed     Abstract available
     
     
     
203. FENG GS, Hanley KL, Liang Y, Lin X, et al
     Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
     Hepatology. 2021;73 Suppl 1:104-114.
     PubMed     Abstract available
     
     
     
204. RIZVI S, Wang J, El-Khoueiry AB
     Liver Cancer Immunity.
     Hepatology. 2021;73 Suppl 1:86-103.
     PubMed    
     
     
     
205. LU X, Paliogiannis P, Calvisi DF, Chen X, et al
     Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
     Hepatology. 2021;73 Suppl 1:49-61.
     PubMed     Abstract available
     
     
     December 2020
206. KOUKOULIOTI E, Ziagaki A, Weber SN, Lammert F, et al
     Long-term colestyramine treatment prevents cholestatic attacks in refractory benign recurrent intrahepatic cholestasis type 1 disease.
     Hepatology. 2020 Dec 5. doi: 10.1002/hep.31671.
     PubMed     Abstract available
     
     
     November 2020
207. KNOOIHUIZEN SAI, Aday A, Lee WM
     Ketamine-Induced Sclerosing Cholangitis (KISC) in a Critically Ill Patient with COVID-19.
     Hepatology. 2020 Nov 23. doi: 10.1002/hep.31650.
     PubMed     Abstract available
     
     
     
208. MOUSA OY, Juran BD, McCauley BM, Vesterhus MN, et al
     Bile Acid Profiles in Primary Sclerosing Cholangitis and their Ability to Predict Hepatic Decompensation.
     Hepatology. 2020 Nov 23. doi: 10.1002/hep.31652.
     PubMed     Abstract available
     
     
     
209. KUNST RF, Verkade HJ, Oude Elferink RPJ, van de Graaf SFJ, et al
     Targeting the four pillars of enterohepatic bile salt cycling; lessons from genetics and pharmacology.
     Hepatology. 2020 Nov 22. doi: 10.1002/hep.31651.
     PubMed     Abstract available
     
     
     
210. SATO K, Zhang W, Safarikia S, Isidan A, et al
     Organoids and spheroids as novel models for studying cholestatic liver injury and cholangiocarcinoma.
     Hepatology. 2020 Nov 22. doi: 10.1002/hep.31653.
     PubMed     Abstract available
     
     
     
211. COLYN L, Barcena-Varela M, Alvarez-Sola G, Latasa MU, et al
     Dual targeting of G9a and DNMT1 for the treatment of experimental cholangiocarcinoma.
     Hepatology. 2020 Nov 22. doi: 10.1002/hep.31642.
     PubMed     Abstract available
     
     
     
212. MEADOWS V, Francis H
     DCLK1 in Cholangiocarcinoma: Is this the biomarker and target we've been looking for?
     Hepatology. 2020 Nov 11. doi: 10.1002/hep.31630.
     PubMed     Abstract available
     
     
     
213. SMETS L, Verbeek J, Korf H, van der Merwe S, et al
     Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate.
     Hepatology. 2020 Nov 3. doi: 10.1002/hep.31613.
     PubMed     Abstract available
     
     
     October 2020
214. XU Y, Zhu Y, Hu S, Xu Y, et al
     Hepatocyte nuclear factor 4alpha prevents the steatosis-to-NASH progression by regulating p53 and bile acid signaling.
     Hepatology. 2020 Oct 23. doi: 10.1002/hep.31604.
     PubMed     Abstract available
     
     
     
215. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
     Liver metastases of intrahepatic cholangiocarcinoma: implications for a potential new staging system.
     Hepatology. 2020 Oct 18. doi: 10.1002/hep.31598.
     PubMed     Abstract available
     
     
     
216. BRAGELMANN J, Barahona Ponce C, Marcelain K, Roessler S, et al
     Epigenome-wide analysis of methylation changes in the sequence of gallstone disease, dysplasia, and gallbladder cancer.
     Hepatology. 2020 Oct 5. doi: 10.1002/hep.31585.
     PubMed     Abstract available
     
     
     
217. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
     Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
     Hepatology. 2020;72:1310-1326.
     PubMed     Abstract available
     
     
     September 2020
218. NEVI L, Di Matteo S, Carpino G, Zizzari I, et al
     DCLK1, a putative novel stem cell marker in human cholangiocarcinoma.
     Hepatology. 2020 Sep 25. doi: 10.1002/hep.31571.
     PubMed     Abstract available
     
     
     
219. EATON JE, Welle CL, Bakhshi Z, Sheedy SP, et al
     Early cholangiocarcinoma detection with magnetic resonance imaging versus ultrasound in primary sclerosing cholangitis.
     Hepatology. 2020 Sep 25. doi: 10.1002/hep.31575.
     PubMed     Abstract available
     
     
     August 2020
220. LEUNG KK, James PD, Jaberi A, Hirschfield GM, et al
     Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding.
     Hepatology. 2020 Aug 11. doi: 10.1002/hep.31519.
     PubMed     Abstract available
     
     
     July 2020
221. DU Y, Khandekar G, Llewellyn J, Polacheck W, et al
     Reply to letter to the editor: Comment on "a bile duct-on-a-chip with organ-level functions".
     Hepatology. 2020 Jul 21. doi: 10.1002/hep.31471.
     PubMed     Abstract available
     
     
     
222. SCHULTHEISS C, Simnica D, Willscher E, Oberle A, et al
     Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis.
     Hepatology. 2020 Jul 21. doi: 10.1002/hep.31473.
     PubMed     Abstract available
     
     
     
223. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
     Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
     Hepatology. 2020;72:359-360.
     PubMed    
     
     
     April 2020
224. ADAMS JM, Huppert KA, Castro EC, Lopez MF, et al
     Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.
     Hepatology. 2020;71:1331-1349.
     PubMed     Abstract available
     
     
     March 2020
225. LU ZN, Luo Q, Zhao LN, Shi Y, et al
     The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
     Hepatology. 2020;71:929-942.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge.